XML 18 R5.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Other Comprehensive Loss
Total
Balance at Jun. 30, 2022 $ 27,076 $ 28,072,855 $ (23,094,272) $ (121,941) $ 4,883,718
Balance (in shares) at Jun. 30, 2022 27,075,648        
Fair value of vested stock options   338,973     338,973
Fair value of vested restricted common stock $ 2,355 923,195     925,550
Fair value of vested restricted common stock (in shares) 2,354,834        
Forfeited restricted common stock $ (65) 65      
Forfeited restricted common stock (in shares) (65,165)        
Repurchase of common stock $ (38) (74,518)     (74,556)
Repurchase of common stock (in shares) (38,585)        
Fair value of vested unrestricted common stock $ 36 68,236     68,272
Fair value of vested unrestricted common stock (in shares) 36,509        
Common stock issued upon exercise of stock options $ 137 57,363     57,500
Common stock issued upon exercise of stock options (in shares) 137,523        
Net income for the period     195,877   195,877
Foreign currency translation       (2,801) (2,801)
Balance at Mar. 31, 2023 $ 29,501 29,386,169 (22,898,395) (124,742) 6,392,533
Balance (in shares) at Mar. 31, 2023 29,500,764        
Balance at Jun. 30, 2022 $ 27,076 28,072,855 (23,094,272) (121,941) 4,883,718
Balance (in shares) at Jun. 30, 2022 27,075,648        
Balance at Jun. 30, 2023 $ 29,487 29,941,873 (22,522,649) (118,224) 7,330,487
Balance (in shares) at Jun. 30, 2023 29,487,508        
Balance at Dec. 31, 2022 $ 29,155 28,874,383 (23,135,237) (120,593) 5,647,708
Balance (in shares) at Dec. 31, 2022 29,154,737        
Fair value of vested stock options   37,236     37,236
Fair value of vested restricted common stock $ 333 442,890     443,223
Fair value of vested restricted common stock (in shares) 332,500        
Forfeited restricted common stock $ (65) 65      
Forfeited restricted common stock (in shares) (65,165)        
Repurchase of common stock $ (13) (25,814)     (25,827)
Repurchase of common stock (in shares) (12,785)        
Common stock issued upon exercise of stock options $ 91 57,409     57,500
Common stock issued upon exercise of stock options (in shares) 91,477        
Net income for the period     236,842   236,842
Foreign currency translation       (4,149) (4,149)
Balance at Mar. 31, 2023 $ 29,501 29,386,169 (22,898,395) (124,742) 6,392,533
Balance (in shares) at Mar. 31, 2023 29,500,764        
Balance at Jun. 30, 2023 $ 29,487 29,941,873 (22,522,649) (118,224) 7,330,487
Balance (in shares) at Jun. 30, 2023 29,487,508        
Fair value of vested stock options   104,502     104,502
Fair value of vested restricted common stock $ 380 1,603,440     1,603,820
Fair value of vested restricted common stock (in shares) 380,000        
Forfeited restricted common stock $ (200) 200      
Forfeited restricted common stock (in shares) (200,000)        
Repurchase of common stock $ (186) (521,838)     $ (522,024)
Repurchase of common stock (in shares) (186,148)        
Common stock issued upon exercise of stock options $ 71 (71)      
Common stock issued upon exercise of stock options (in shares) 71,050       371,883
Common stock issued for acquisition of Scite $ 2,729 6,546,905     $ 6,549,634
Common stock issued for acquisition of Scite (in shares) 2,729,014        
Modification cost of accelerated vesting of restricted common stock   20,949     20,949
Net income for the period     (965,370)   (965,370)
Foreign currency translation       6,261 6,261
Balance at Mar. 31, 2024 $ 32,281 37,695,960 (23,488,019) (111,963) 14,128,259
Balance (in shares) at Mar. 31, 2024 32,281,424        
Balance at Dec. 31, 2023 $ 32,620 37,607,895 (23,564,320) (112,821) 13,963,374
Balance (in shares) at Dec. 31, 2023 32,619,598        
Fair value of vested stock options   42,788     42,788
Fair value of vested restricted common stock   498,214     498,214
Forfeited restricted common stock $ (200) 200      
Forfeited restricted common stock (in shares) (200,000)        
Repurchase of common stock $ (159) (453,117)     (453,276)
Repurchase of common stock (in shares) (159,044)        
Common stock issued upon exercise of stock options $ 20 (20)      
Common stock issued upon exercise of stock options (in shares) 20,870        
Net income for the period     76,301   76,301
Foreign currency translation       858 858
Balance at Mar. 31, 2024 $ 32,281 $ 37,695,960 $ (23,488,019) $ (111,963) $ 14,128,259
Balance (in shares) at Mar. 31, 2024 32,281,424